{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:01:23Z","timestamp":1787288483402,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.schres.2013.10.034","type":"journal-article","created":{"date-parts":[[2013,11,23]],"date-time":"2013-11-23T02:45:41Z","timestamp":1385174741000},"page":"246-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary"],"prefix":"10.1016","volume":"152","author":[{"given":"Lajos","family":"Katona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e1l","family":"Czobor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"Bitter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2013.10.034_bb0005","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2147\/NDT.S30268","article-title":"Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia","volume":"8","author":"Ascher-Svanum","year":"2012","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.schres.2013.10.034_bb0010","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/YCO.0b013e32835d9efb","article-title":"Polypharmacy for schizophrenia","volume":"26","author":"Ballon","year":"2013","journal-title":"Curr. Opin. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0015","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/schbul\/sbn030","article-title":"Does the addition of a second antipsychotic drug improve clozapine treatment?","volume":"35","author":"Barbui","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.10.034_bb0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.2165\/11587810-000000000-00000","article-title":"Antipsychotic polypharmacy in schizophrenia: benefits and risks","volume":"25","author":"Barnes","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2013.10.034_bb0025","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.euroneuro.2007.08.001","article-title":"Antipsychotic prescription patterns in outpatient settings: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study","volume":"18","author":"Bitter","year":"2008","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2013.10.034_bb0030","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1524-4733.2007.00262.x","article-title":"Duration of antipsychotic drug therapy in real-world practice: a comparison with CATIE trial results","volume":"11","author":"Chen","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.schres.2013.10.034_bb0035","first-page":"CD006324","article-title":"Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia","author":"Cipriani","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2013.10.034_bb0040","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","article-title":"Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials","volume":"35","author":"Correll","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.schres.2013.10.034_bb0045","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and lifetables","volume":"34","author":"Cox","year":"1972","journal-title":"J. R. Stat. Soc."},{"key":"10.1016\/j.schres.2013.10.034_bb0050","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","article-title":"Effectiveness of switching from antipsychotic polypharmacy to monotherapy","volume":"168","author":"Essock","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","article-title":"Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics","volume":"5","author":"Faries","year":"2005","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0060","series-title":"Federal Coordinating Council for Comparative Effectiveness Research Report to the President and the Congress","author":"Federal Coordinating Council","year":"2009"},{"key":"10.1016\/j.schres.2013.10.034_bb0070","article-title":"Critical review of antipsychotic polypharmacy in the treatment of schizophrenia","volume":"1\u201311","author":"Fleischhacker","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl. B","key":"10.1016\/j.schres.2013.10.034_bb0065","first-page":"78","article-title":"Clozapine dose in the United States and Europe: implications for therapeutic and adverse effects","volume":"55","author":"Fleischhacker","year":"1994","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0075","series-title":"Public Law 110-85: Food and Drug Administration Amendments Act of 2007","author":"Food and Drug Administration","year":"2007"},{"key":"10.1016\/j.schres.2013.10.034_bb0080","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1056\/NEJMe058200","article-title":"The choice of antipsychotic drugs for schizophrenia","volume":"353","author":"Freedman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2013.10.034_bb9000","article-title":"Characteristics and trends of low-dose quetiapine use in two western state Medicaid programs","author":"Hartung","year":"2013","journal-title":"Pharmacoepi. and drug safety"},{"key":"10.1016\/j.schres.2013.10.034_bb0085","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple test of significance","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"10.1016\/j.schres.2013.10.034_bb0090","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/00023210-200721090-00001","article-title":"Conceptual and methodological issues in the design of clinical trials of antipsychotics for the treatment of schizophrenia","volume":"21","author":"Honer","year":"2007","journal-title":"CNS Drugs"},{"key":"10.1016\/j.schres.2013.10.034_bb0095","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1176\/appi.ajp.162.1.130","article-title":"Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial","volume":"162","author":"Josiassen","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0100","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2013.10.034_bb0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","article-title":"Long-term combination antipsychotic treatment in VA patients with schizophrenia","volume":"84","author":"Kreyenbuhl","year":"2006","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.10.034_bb0110","first-page":"1","article-title":"Practice guideline for the treatment of patients with schizophrenia, second edition","volume":"161","author":"Lehman","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2013.10.034_bb0120","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/JCP.0b013e3181f28dff","article-title":"A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia","volume":"30","author":"Lin","year":"2010","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2013.10.034_bb0125","series-title":"Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care (Update), Final Version (NICE Clinical Guideline 82)","author":"NICE","year":"2009"},{"key":"10.1016\/j.schres.2013.10.034_bb0130","author":"Norwegian Institute of Public Health"},{"key":"10.1016\/j.schres.2013.10.034_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/S1461145704004262","article-title":"A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis","volume":"7","author":"Oosthuizen","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2013.10.034_bb0140","series-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2009"},{"key":"10.1016\/j.schres.2013.10.034_bb0145","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2008.09.031","article-title":"Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial","volume":"107","author":"Rosenheck","year":"2009","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2013.10.034_bb0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1056\/NEJMoa1005987","article-title":"Long-acting risperidone and oral antipsychotics in unstable schizophrenia","volume":"364","author":"Rosenheck","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.schres.2013.10.034_bb0155","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1185\/030079907X233359","article-title":"Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorder","volume":"23","author":"Rupnow","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2013.10.034_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v042.i07","article-title":"Multivariate and propensity score matching software with automated balance optimization: the matching package for R","volume":"42","author":"Sekhon","year":"2011","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.schres.2013.10.034_bb0165","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.38881.382755.2F","article-title":"Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study","volume":"333","author":"Tiihonen","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.schres.2013.10.034_bb0175","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2013.10.034_bb0170","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0180","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","article-title":"Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia","volume":"69","author":"Tiihonen","year":"2012","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.schres.2013.10.034_bb0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00002018-200831010-00002","article-title":"Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature","volume":"31","author":"Tranulis","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.schres.2013.10.034_bb0195","first-page":"3","article-title":"Treatment of schizophrenia 1999. The expert consensus guideline series","volume":"60","author":"Treatment of schizophrenia","year":"1999"},{"key":"10.1016\/j.schres.2013.10.034_bb0200","series-title":"Clinical Descriptions and Diagnostic Guidelines","article-title":"The ICD-10 classification of mental and behavioural disorders","author":"World Health Organization","year":"1992"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413005847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996413005847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T07:44:09Z","timestamp":1716191049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996413005847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S0920996413005847"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2013.10.034","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: To switch or to combine? A nationwide study in Hungary","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2013.10.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}